{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-035793","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2026-05-18T10:47:00+00:00","discovered_at":"2026-05-18T10:50:00.359716+00:00","generated_at":"2026-05-18T10:50:45.780490+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total","bullets":["Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.","License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.","BioAtla no longer entitled to future milestones or royalties for CT-202.","Phase 1 trial initiation for CT-202 expected in Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-035793","json":"https://secwatch.observer/filing/0001628280-26-035793.json","markdown":"https://secwatch.observer/filing/0001628280-26-035793.md","text":"https://secwatch.observer/filing/0001628280-26-035793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/0001628280-26-035793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/cntx-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:50:45.780490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72fb36945a094344fe94e5f903126e5db5d92e1d","claim":"Context Therapeutics Inc. amended First Amendment to License Agreement with BioAtla, Inc. valued at $4.5 million within five business days of the Amendment Date and an additional $2.0 million by Augus (effective 2026-05-14).","evidence_excerpt":"On May 14, 2026 (the “Amendment Date”), Context Therapeutics Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to that certain License Agreement, dated September 23, 2024, by and between the Company and BioAtla, Inc. (“BioAtla”) (the “Original License Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/0001628280-26-035793-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"BioAtla, Inc."},{"label":"Value","value":"$4.5 million within five business days of the Amendment Date and an additional $2.0 million by Augus"},{"label":"Effective","value":"2026-05-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}